Drug Profile
Research programme: cannabinoid receptor CB2 agonists - Pfizer
Alternative Names: AR-XYZLatest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Class
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis; Pain
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 03 May 2016 Discontinued - Early research for Osteoarthritis in USA (PO)
- 03 May 2016 Discontinued - Preclinical for Pain in USA (PO)